EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--OneMedNet Corporation (“OneMedNet” or the “Company”), an experienced curator of regulatory-grade Imaging Real Word Data ("RWD"), announced today the Company has built one of the largest and most diverse dataset of breast cancer screenings, a vital tool in early detection of breast cancer. OneMedNet’s Breast Imaging Dataset collects insight from over 1 million US patients with emphasis on gathering screenings from a diverse patient population.
“The importance of early detection is critical and provides oncologists with a greater array of treatment options, several of which may be less aggressive and still deliver positive outcomes,” shared Jeffrey Yu, Founder and Chief Medical Officer of OneMedNet. The breast cancer screening dataset is an invaluable tool for AI, imaging and pharma companies looking to bring novel treatments and detection programs to patients faster.
According to Deb Reinhart, Director, Product & Clinical for OneMedNet, “The key to developing better algorithms and novel therapies is to ensure the breast screening population is diverse in terms of race, ethnicity and tissue density.”
With access to OneMedNet’s Breast Imaging Dataset, researchers can create algorithms that better identify cancer as well as the discovery and development of novel cancer therapies faster.
Founded in 2009, OneMedNet unlocks the significant value contained within the clinical image archives of healthcare providers by transforming Real-World Data into a valuable, quality asset that can help clinicians improve care and lower costs. Employing its proven OneMedNet iRWD™ solution, OneMedNet securely de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with industry leading technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous Real-World Data Life Science requirements. OneMedNet is led by its Chief Executive Officer, Paul Casey and Chief Medical Officer, Dr. Jeffrey Yu.